Ask AI
PBC Consult
PBC Consult: Customized Treatment Recommendations for Individual Patient Cases

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Released: March 31, 2026

References

1.     Invernizzi P, Floreani A, Carbone M et al. Primary biliary cholangitis: advances in management and treatment of the disease. Dig Liver Dis. 2017;49:841-846.

2.     Ursodiol [prescribing information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; 2024.

3.     Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394-419.

4.     Levy C, Manns M, Hirschfied G. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol. 2023;21:2076-2087.

5.     Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56:198-208.

6.     Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147:1338-1349.

7.     Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871-877.

8.     Cheung AC, Lammers WJ, Murillo Perez CF, et al. Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis. Clin Gastroenterol Hepatol. 2019;17:2076-2084 e2.

9.     Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterol. 2009;126:1281-1287.

10. Murillo Perez CF, Ioannou S, Hassanally I, et al. Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival. Liver Int. 2023;43:1497-1506.

11. Hirschfield, GM, Dyson JK, Alexander GJ, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67:1568-1594.

Access to and use of this Interactive Decision Support Tool titled, “PBC Consult: Customized Treatment Recommendations for Individual Patient Cases" is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for patients with primary biliary cholangitis (PBC) who are already receiving first-line therapy. The information provided is based on the expert guidance of Alan Bonder, MD, AGAF; Aparna Goel, MD; Sonal Kumar, MD, MPH; Daniel S. Pratt, MD, FAASLD; and Mark Swain, MD, MSc, FRCPC, FAASLD, FCAHS.

The material published by Decera Clinical Education reflects the views of the reviewers or authors of the CCO material, not those of Decera Clinical Education, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “PBC Consult: Customized Treatment Recommendations for Individual Patient Cases” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education including, but not limited to, medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2026 Clinical Care Options, LLC dba Decera Clinical Education. All rights reserved.

Program Content